We are live on ! Find out more
VMI

VHCP Management II Portfolio holdings

AUM $379M
1-Year Est. Return 421.62%
This Fund
S&P 500
This Quarter Est. Return
+5.55%
1 Year Est. Return
+421.62%
3 Year Est. Return
+2,333.62%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$166M
AUM Growth
+$13.7M
Cap. Flow
+$14.4M
Cap. Flow %
8.71%
Top 10 Hldgs %
80.8%
Holding
23
New
1
Increased
3
Reduced
1
Closed
–

Top Buys

1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$3.2M
2
SYRE icon
Spyre Therapeutics
SYRE
+$2.68M
3
ARCT icon
Arcturus Therapeutics
ARCT
+$1.46M

Top Sells

1
RGNX icon
Regenxbio
RGNX
+$348K

Sector Composition

1 Healthcare 85.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVXS
1
DELISTED
AveXis, Inc. Common Stock
AVXS
$37.8M 22.81%
1,035,657
– –
PDSB icon
2
PDS Biotechnology
PDSB
$41.1M
$19.5M 11.8%
96,679
– –
BCRX icon
3
BioCryst Pharmaceuticals
BCRX
$2.36B
$16.2M 9.81%
5,721,142
+1,031,707
+22% +$3.2M
ASND icon
4
Ascendis Pharma A/S
ASND
$17.1B
$9.57M 5.78%
721,152
– –
RGNX icon
5
Regenxbio
RGNX
$511M
$8M 4.83%
999,633
-31,321
-3% -$348K
HRTX icon
6
Heron Therapeutics
HRTX
$89.1M
$7.33M 4.42%
405,901
– –
ARCT icon
7
Arcturus Therapeutics
ARCT
$172M
$6.53M 3.94%
207,772
+46,272
+29% +$1.46M
CTMX icon
8
CytomX Therapeutics
CTMX
$788M
$5.91M 3.56%
577,831
– –
SIOX
9
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$5.52M 3.33%
53,699
– –
AKTX
10
Akari Therapeutics
AKTX
$19.3M
$4.98M 3.01%
462
– –
CHRS icon
11
Coherus Oncology
CHRS
$216M
$4.38M 2.64%
259,259
– –
ONC
12
BeOne Medicines Ltd
ONC
$32.4B
$3.55M 2.14%
119,000
– –
ORKA
13
Oruka Therapeutics
ORKA
$5.59B
$3.13M 1.89%
4,995
– –
GBT
14
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.83M 1.71%
170,312
– –
STML
15
DELISTED
Stemline Therapeutics, Inc.
STML
$2.14M 1.29%
315,980
– –
OCRX
16
DELISTED
Ocera Therapeutics, Inc.
OCRX
$1.8M 1.09%
948,372
– –
SYRE icon
17
Spyre Therapeutics
SYRE
$8.7B
$1.53M 0.92%
+14,005
New +$2.68M
LPCN icon
18
Lipocine
LPCN
$18.4M
$1.28M 0.77%
24,706
– –
ADVM
19
DELISTED
Adverum Biotechnologies
ADVM
$885K 0.53%
28,000
– –
LRMR icon
20
Larimar Therapeutics
LRMR
$384M
$847K 0.51%
11,790
– –
SRRA
21
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$260K 0.16%
3,270
– –

Similar funds

ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
PI
PHH Investments Addison, Texas $378M AUM 19.74% 1-Year Est. Return
SC
Southside Capital Miami Beach, Florida $382M AUM 30.29% 1-Year Est. Return
FFSOTS
Fiduciary Financial Services of The Southwest Dallas, Texas $382M AUM 25.98% 1-Year Est. Return
PC
Passport Capital San Francisco, California $394M AUM 50.67% 1-Year Est. Return
WC
Whitnell & Co Oak Brook, Illinois $326M AUM 25.97% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
LB
Landmark Bank Columbia, Missouri $444M AUM 30.12% 1-Year Est. Return

VHCP Management II's Q2 2016 Portfolio in Review

As of Q2 2016, VHCP Management II held 23 positions worth $166M, up 9% from $152M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

VHCP Management II deployed $14.4M of net new capital in Q2 2016, opening 1 new position and adding to 3 existing holdings. Its largest new stake was Spyre Therapeutics: 14,005 shares worth $1.53M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 88% a quarter earlier.

On the sell side, the largest reduction was Regenxbio, an estimated $348K trimmed.

  • VHCP Management II's largest Q2 2016 buy was Spyre Therapeutics: 14,005 shares worth $1.53M.
  • VHCP Management II added most to BioCryst Pharmaceuticals in Q2 2016, an estimated $3.2M increase.
  • VHCP Management II's biggest Q2 2016 reduction was Regenxbio, cutting an estimated $348K.
  • VHCP Management II's ten largest holdings make up 81% of its $166M portfolio in Q2 2016.
  • VHCP Management II opened 1 new position and closed 0 in Q2 2016.
  • VHCP Management II's portfolio value rose 9% quarter-over-quarter to $166M.

Based on VHCP Management II's 13F filing for Q2 2016, filed 12 Aug 2016.